^
Association details:
| Biomarker: | NRG1 fusion |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | zenocutuzumab (MCLA-128) (HER2 inhibitor, HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Published date:
10/16/2023
Excerpt:
In this updated analysis, Zeno continues to demonstrate unprecedented efficacy in pts with previously treated advanced/metastatic NRG1+ PDAC with robust and durable responses and a well-tolerated safety profile.
Trial ID:
